Jones v. Allercare, Inc.

203 F.R.D. 290, 2001 U.S. Dist. LEXIS 1574, 2001 WL 1148133
CourtDistrict Court, N.D. Ohio
DecidedFebruary 2, 2001
DocketNo. 1:00CV257
StatusPublished
Cited by17 cases

This text of 203 F.R.D. 290 (Jones v. Allercare, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Allercare, Inc., 203 F.R.D. 290, 2001 U.S. Dist. LEXIS 1574, 2001 WL 1148133 (N.D. Ohio 2001).

Opinion

Memorandum of Opinion and Order

GAUGHAN, District Judge.

INTRODUCTION

This matter is before the Court- upon Plaintiffs’ Motion for Class Certification (Doc. 52). This case arises out of plaintiffs’ alleged personal injury and property damage following the application of AllerCare Dust Mite Carpet Powder (hereafter “Powder”) and/or AllerCare Dust Mite Allergen Spray (hereafter “Spray”) to carpeting and/or furniture. For the following reasons, the Motion is DENIED.

FACTS

Plaintiffs are residents of Ohio.1 (Compl.¶ 2). Defendant is a Wisconsin corporation and the manufacturer of the Powder and Spray.2 (Compl.¶ 9). Defendant marketed and distributed the Powder and Spray from August 1999 through January 2000, when the products were removed from the marketplace. (Compl.¶ 9). The Powder and Spray were formulated for household application to carpeting and furniture for the pur[293]*293pose of controlling dust mite allergens. (Mitchell Aff, Ex. A). The products were marketed to a target group of consumers with asthma and allergies. (Archer & Soto Depos., Ex. 2 at 2-3). Plaintiffs allege, however, that defendant knew or should have known that the Powder and Spray would cause adverse reactions among consumers in general and the target group in particular.

Plaintiffs allege that these adverse reactions were caused in part by the active ingredient, benzyl benzoate. Plaintiffs point out that the United States Environmental Protection Agency (hereafter “U.S. EPA”), observed in its Review of Allercare that “[t]here is scientific literature on benzyl benzoate which bears on its potential to cause adverse effects.” (Archer & Soto Depos., Ex. 21 at 7). On the other hand, defendant notes that benzyl benzoate has GRAS (Generally Recognized As Safe) status with the Food and Drug Administration and is approved for use as a food additive. (Mitchell Aff., Ex. A). The Powder contains a benzyl benzoate level of 4.6%. (Archer & Soto Depos., Ex. 21 at 2). The Spray contains a benzyl benzoate level of 18%. (Archer & Soto Depos., Ex. 21 at 2).

In addition, plaintiffs allege that a fragrance in the Powder and Spray was known by defendant to be a trigger for adverse reactions in persons with asthma or allergies. (Archer & Soto Depos., Ex. 1 at 3). Plaintiffs point to defendant’s statement that “[l]iterature references support an association of fragrance/perfume and asthma related effects” as an admission. (Supp.Ex. S-1). Product Safety Resources (hereafter “Prosar”), - one of defendant’s contractors, also noted, “Fragrances have been increasingly cited as ‘triggers’ of asthma attacks in published peer-reviewed journals.” (Archer & Soto Depos., Ex. 30 at 1).

Plaintiffs also allege that the Material Safety Data Sheets for the Powder and Spray confirm that defendant was aware of the propensity of the products to cause respiratory irritation, eye irritation and irritation of the skin. (Archer & Soto Depos., Ex. 18 at 1 & 19 at 1). According to plaintiffs, defendant ignored this fact and included unusually high levels of fragrance in the Powder and Spray. In a response to inquiries by the U.S. EPA regarding the products, defendant stated, “Note that the fragrance levels at 0.72% and 0.4% in the aerosol and carpet powder respectively are relatively high for household cleaning or pesticide products.” (Archer & Soto Depos., Ex. 22 at 2).

Test Marketing Period

During the test marketing period, defendant retained Prosar and utilized its Consumer Resource Center to receive and compile reports from consumers who dialed the 800 number listed on the Powder and Spray labels. (Mitchell Aff., Ex. A). Janet C. Mitchell, defendant’s Consumer Liability Manager, avers,

Customers who called that number initially spoke with personnel employed by ALTA Resources which is located in Neenah, Wisconsin. ALTA personnel provided general information about such things as product availability and proper usage instructions. If a caller stated that she or he had any type of medical complaint or expressed a concern about the product which the ALTA representative could not answer, the caller was transferred immediately to S.C. Johnson’s in-house Consumer Resource Center. Additionally, these callers were given the telephone number of Product Safety Resources (Prosar), an independent medical information center, that S.C. Johnson has retained to respond to the inquiries of its customers 24 hours a day.

(Mitchell Aff., Ex. A).

Plaintiffs allege that immediately after the introduction of the Powder and Spray into test markets, symptoms known to be associated with benzyl benzoate and/or the fragrance ingredient were reported by consumers. For example, between August 3 and October 25,1998, defendant received six calls to its Medical Emergency System. (Archer & Soto Depos., Ex. 7 at 1). However, defendant determined that the “medical severity of these calls [was] very low” and recommended that no action be taken, but the reports continue to be monitored. (Archer & Soto Depos., Ex. 7 at 1). Plaintiffs also allege that during the test marketing period, defendant was warned by a physician about the [294]*294effects of the Powder and Spray on persons with asthma and allergies. (Supp.Ex. S-2).

Plaintiffs allege that at the end of the test marketing period, defendant was concerned that the Powder and Spray “might trigger an attack in asthmatics or cause difficulties in allergen-sensitive individuals.” (Archer & Soto Depos., Ex. 1 at 3). Because of this, defendant hired Pegus Research, Inc. (hereafter “Pegus”) to analyze the causal relationship between the reported symptoms and the Powder and Spray. (Archer & Soto Depos., Ex. 1 at 3).

Product Release

The Powder and Spray were introduced into the regular consumer market in August 1999. (Mitchell Aff. ¶ 5). The first reported incident relating to the use of the Powder or Spray occurred on August 30, 1999. (Archer & Soto Depos., Ex. 21 at 3). Plaintiffs allege that over the next five months, the reports of adverse reactions increased in direct correlation to the number of units sold; (Archer & Soto Depos., Ex. 5 at 3-4).

An investigator at the U.S. EPA analyzed the number and frequency of reports involving adverse reactions to the Powder and Spray on January 11, 2000. (Archer & Soto Depos., Ex. 21). The investigator stated that, if the number of reports were extrapolated for a full year, “the Allercare Dust Mite Powder almost certainly would account for more serious cases (moderate and major outcome) than any single pesticide product in the residential market.” (Archer & Soto Depos., Ex. 21 at 5). Plaintiffs allege that defendant surreptitiously obtained a copy of this report on January 14, 2000. (Archer & Soto Depos., Ex. 21 at 1). However, the U.S. EPA website indicates that it “urged SC Johnson to immediately remove” the Powder and Spray from the marketplace and that defendant had already agreed to do so as of January 14, 2000. (Archer & Soto Depos., Ex.31 at 1). On that date, defendant “committed to immediately stop production and shipment of these products and to remove these products from the marketplace.” (Archer & Soto Depos., Ex. 31 at 1). The announcement also stated, “Because of the relatively large number of incidents reported in such a short time frame, EPA urged [defendant] to immediately initiate this product recall.” (Ex.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States ex rel. Holbrook v. Brink's Co.
336 F. Supp. 3d 860 (S.D. Ohio, 2018)
Jones v. Corbis Corp.
815 F. Supp. 2d 1108 (C.D. California, 2011)
Schnall v. AT&T Wireless Services, Inc.
171 Wash. 2d 260 (Washington Supreme Court, 2011)
Schnall v. AT & T WIRELESS SERVICES, INC.
259 P.3d 129 (Washington Supreme Court, 2011)
Taylor v. CSX Transportation, Inc.
264 F.R.D. 281 (N.D. Ohio, 2007)
Gartin v. S & M NuTec LLC
245 F.R.D. 429 (C.D. California, 2007)
Pettrey v. Enterprise Title Agency, Inc.
241 F.R.D. 268 (N.D. Ohio, 2006)
Sweet v. Pfizer
232 F.R.D. 360 (C.D. California, 2005)
Dage v. Time Warner Cable
395 F. Supp. 2d 668 (S.D. Ohio, 2005)
Henry Schein, Inc. v. Stromboe
102 S.W.3d 675 (Texas Supreme Court, 2002)
In Re CommonPoint Mortgage Co.
283 B.R. 469 (W.D. Michigan, 2002)
Jaros v. E.I. DuPont
292 F.3d 1124 (Ninth Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
203 F.R.D. 290, 2001 U.S. Dist. LEXIS 1574, 2001 WL 1148133, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-allercare-inc-ohnd-2001.